betrixaban   Click here for help

GtoPdb Ligand ID: 9602

Synonyms: Bevyxxa® | compound 11 [PMID: 19297154] | PRT-054021 | PRT054021
Approved drug
betrixaban is an approved drug (FDA (2017))
Compound class: Synthetic organic
Comment: Betrixaban is an orally active direct factor Xa inhibitor [1], that is an approved anti-thrombotic.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 107.41
Molecular weight 451.14
XLogP 5.04
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES COc1ccc(c(c1)C(=O)Nc1ccc(cn1)Cl)NC(=O)c1ccc(cc1)C(=N)N(C)C
Isomeric SMILES COc1ccc(c(c1)C(=O)Nc1ccc(cn1)Cl)NC(=O)c1ccc(cc1)C(=N)N(C)C
InChI InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31)
No information available.
Summary of Clinical Use Click here for help
Betrixaban was FDA approved in June 2017 for extended duration prophylaxis (35 to 42 days) of venous thromboembolism (VTE), in hospitalized patients at risk for thromboembolic complications.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Serine protease factor Xa catalyzes the conversion of prothrombin to thrombin, the final enzyme responsible for fibrin clot formation in the blood coagulation cascade. Direct inhibition of factor Xa has anti-thrombotic action, and small molecule factor Xa inhibitors are used clinically.